Residual tumor micro-foci and overwhelming regulatory T lymphocyte infiltration are the causes of bladder cancer recurrence

Oncotarget

Volumn 7, Issue 6, 2016, Pages 6424-6435

  Parodi, Alessia ^a   Traverso, Paolo ^a,b   Kalli, Francesca ^a   Conteduca, Giuseppina ^a   Tardito, Samuele ^a   Curto, Monica ^a   Grillo, Federica ^a,b   Mastracci, Luca ^a,b   Bernardi, Cinzia ^a   Nasi, Giorgia ^a   Minaglia, Francesco ^a,b   Simonato, Alchiede ^a,b   Carmignani, Giorgio ^a,b   Ferrera, Francesca ^a   Fenoglio, Daniela ^a,b,c   Filaci, Gilberto ^a,b,c  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Bladder cancer; Immune response; Immunity; Immunology and microbiology section; Mage; Th1; Th17; Tumor infiltrating lymphocytes

Indexed keywords

CD28 ANTIGEN; CD39 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 2; MAGEA1 PROTEIN, HUMAN; MAGEA2 PROTEIN, HUMAN; MELANOMA ANTIGEN; MESSENGER RNA; TUMOR PROTEIN;

ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CANCER SUSCEPTIBILITY; CLINICAL ARTICLE; GENE EXPRESSION; GENE FREQUENCY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; LYMPHOCYTE COUNT; LYMPHOCYTIC INFILTRATION; MAGE A1 GENE; MAGE A2 GENE; MINIMAL RESIDUAL DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; BLADDER TUMOR; CASE CONTROL STUDY; CD8+ T LYMPHOCYTE; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; FLUORESCENT ANTIBODY TECHNIQUE; FOLLOW UP; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR RECURRENCE;

CASE-CONTROL STUDIES; CD8-POSITIVE T-LYMPHOCYTES; FLUORESCENT ANTIBODY TECHNIQUE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA-SPECIFIC ANTIGENS; NEOPLASM GRADING; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES, REGULATORY; URINARY BLADDER NEOPLASMS;

EID: 84980598857     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7024     Document Type: Article

References (29)

1. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009; 27: 289-293.
2. Huang GJ, Stein JP. Open radical cystectomy with lymphadenectomy remains the treatment of choice for invasive bladder cancer. Curr Opin Urol. 2007; 17: 369-375.
3. Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD. Superficial bladder cancer: progression and recurrence. J Urol. 1983; 130: 1083-1086.
4. Holmäng S, Hedelin H, Anderström C, Johansson SL. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol. 1995; 153: 1823-1826.
5. Sonpavde G, Khan MM, Lerner SP, Svatek RS, Novara G, Karakiewicz PI, Skinner E, Tilki D, Kassouf W, Fradet Y, Dinney CP, Fritsche HM, Izawa JI, et al. Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. J Urol. 2011; 185: 456-461.
6. Stein JP, Skinner DG. Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol. 2006; 24: 296-304.
7. Schrodter S, Hakenberg OW, Manseck A, Leike S, Wirth MP. Outcome of surgical treatment of isolated local recurrence after radical nephrectomy for renal cell carcinoma. J Urol. 2002; 167: 1630-1633.
8. Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, Bajorin DF, Reuter VE, Herr H, Old LJ, Sato E. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. PNAS. 2007; 104: 3967-3972.
9. Yan M, Jene N, Byrne D, Millar EK, O'Toole SA, McNeil CM, Bates GJ, Harris AL, Banham AH, Sutherland RL, Fox SB. Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. Breast Cancer Res. 2011; 13: R47.
10. Goc J, Germain C, Duy Vo-Bourgais TK, Lupo A, Klein C, Knockaert S, de Chaisemartin L, Ouakrim H, Becht E, Alifano M, Validire P, Remark R, et al. Dendritic Cells in Tumor-Associated Tertiary Lymphoid Structures Signal a Th1 Cytotoxic Immune Contexture and License the Positive Prognostic Value of Infiltrating CD8+ T Cells. Cancer Res. 2013; 74: 705-715.
11. Lu L, Pan K, Zheng HX, Li JJ, Qiu HJ, Zhao JJ, Weng DS, Pan QZ, Wang DD, Jiang SS, Chang AE, Li Q, Xia JC. IL-17A promotes immune cell recruitment in human esophageal cancers and the infiltrating dendritic cells represent a positive prognostic marker for patient survival. J Immunother. 2013; 36: 451-458.
12. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer. 2010; 127: 759-767.
13. Whiteside TL, Schuler P, Schilling B. Induced and natural regulatory T cells in human cancer. Expert Opin Biol Ther. 2012; 12: 1383-1397.
14. Fenoglio D, Bernuzzi F, Battaglia F, Parodi A, Kalli F, Negrini S, De Palma R, Invernizzi P, Filaci G. Th17 and regulatory T lymphocytes in primary biliary cirrhosis and systemic sclerosis as models of autoimmune fibrotic diseases. Autoimmun Rev. 2012; 12: 300-304.
15. Parodi A, Battaglia F, Kalli F, Ferrera F, Conteduca G, Tardito S Stringara S, Ivaldi F, Negrini S, Borgonovo G, Simonato A, Traverso P, Carmignani G, et al. CD39 is highly involved in mediating the suppression activity of tumor-infiltrating CD8+ T regulatory lymphocytes. Cancer Immunol Immunother. 2013; 62: 851-862.
16. Filaci G, Fenoglio D, Fravega M, Ansaldo G, Borgonovo G, Traverso P, Villaggio B, Ferrera A, Kunkl A, Rizzi M, Ferrera F, Balestra P, Ghio M, et al. CD8+ CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. J Immunol. 2007; 179: 4323-4334.
17. Patard JJ, Brasseur F, Gil-Diez S, Radvanyi F, Marchand M, François P, Abi-Aad A, Van Cangh P, Abbou CC, Chopin D, Boon T. Expression of MAGE genes in transitional-cell carcinomas of the urinary bladder. Int J Cancer. 1995; 64: 60-64.
18. Yamanaka K, Miyake H, Hara I, Gohji K, Arakawa S, Kamidono S. Expression of MAGE genes in renal cell carcinoma. Int J Mol Med. 1998; 2: 57-60.
19. Castillo-Martin M, Domingo-Domenech J, Karni-Schmidt O, Matos T, Cordon-Cardo C. Molecular pathways of urothelial development and bladder tumorigenesis. Urol Oncol. 2010; 28: 401-408.
20. Bolenz C, Lotan Y. Translational research in bladder cancer: from molecular pathogenesis to useful tissue biomarkers. Cancer Biol Ther. 2010; 10: 407-415.
21. McConkey DJ, Lee S, Choi W, Tran M, Majewski T, Lee S, Siefker-Radtke A, Dinney C, Czerniak B. Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. Urol Oncol. 2010; 28: 429-440.
22. Goebell PJ, Knowles MA. Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol Oncol. 2010; 28: 409-428.
23. Fitzpatrick JM, West AB, Butler MR, Lane V, O'Flynn JD. Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection. J Urol. 1986; 135: 920-922.
24. Pasin E, Josephson DY, Mitra AP, Cote RJ, Stein JP. Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol. 2008; 10: 31-43.
25. Disis ML. Immune Regulation of Cancer. J Clin Oncol. 2010; 28: 4531-4538.
26. Rusakiewicz S1, Semeraro M, Sarabi M, Desbois M, Locher C, Mendez R, Vimond N, Concha A, Garrido F, Isambert N, Chaigneau L, Le Brun-Ly V, Dubreuil P, et al. Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors. Cancer Res. 2013; 73: 3499-3510.
27. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Nagtegaal ID, Palmqvist R, Masucci GV, et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol. 2014; 232: 199-209.
28. Van Batavia J, Yamany T, Molotkov A, Dan H, Mansukhani M, Batourina E, Schneider K, Oyon D, Dunlop M, Wu XR, Cordon-Cardo C, Mendelsohn C. Bladder cancers arise from distinct urothelial sub-populations. Nat Cell Biol. 2014; 16: 982-991.
29. Grillo F, Pigozzi S, Ceriolo P, Calamaro P, Fiocca R, Mastracci L. Factors affecting immunoreactivity in long-term storage of formalin-fixed paraffin-embedded tissue sections. Histochem Cell Biol. 2015; 144: 93-99.